GMP IPO Watch
Q-Line Biotech IPO 2026: Diagnostics and Healthcare Solutions Provider Eyes Growth Amid Rising Demand
Q-Line Biotech IPO has attracted investor attention in the SME market as the company seeks...
Read Article
Q
SME IPO
LISTED
NSE, BSE
QLINEBIOTECH
Q-Line Biotech IPO
Q-Line Biotech IPO details, live grey market premium (GMP), dates, price band, lot size, subscription & review.
Live GMP Today
₹109
+31.8%
Est. Listing: ₹452.00
Price Band
₹326 - ₹343
Per equity share
Lot Size
400 Shares
Min Invest: ₹2,74,400
Issue Size
₹343 Cr
Total Public Offering
Issue Dates
20 May 2026 – 24 May 2026
Bidding period
Subscription
50.82x
Total overall demand
Q-Line Biotech IPO Details
Key facts at a glance| IPO Open Date | 20 May 2026 | IPO Close Date | 24 May 2026 |
|---|---|---|---|
| Basis of Allotment | 25 May 2026 | Listing Date | 28 May 2026 |
| Price Band | ₹326 - ₹343 per share | Face Value | ₹10 per share |
| Market Lot Size | 400 Shares | Min Investment (Retail) | ₹2,74,400 |
| Total Issue Size | ₹343 Cr | Issue Type | Book Built Issue IPO |
| Fresh Issue | — | Offer for Sale (OFS) | — |
| Listing At | NSE, BSE | Issue Category | SME Issue |
| Registrar | TBA | ||
Q-Line Biotech IPO Timetable (Tentative Dates)
| Event | Tentative Date | Status |
|---|---|---|
| IPO Open Date | 20 May 2026 | Confirmed |
| IPO Close Date | 24 May 2026 | Confirmed |
| Basis of Allotment | 25 May 2026 | Tentative |
| Initiation of Refunds | TBA | Tentative |
| Credit of Shares to Demat | TBA | Tentative |
| IPO Listing Date | 28 May 2026 | Tentative |
| Cut-off time for UPI Mandate Confirmation | 5:00 PM on Closing Day | Deadline |
* Note: Timelines are tentative and subject to regulatory confirmation. UPI mandate approvals must be completed by 5:00 PM on the IPO closing day.
Q-Line Biotech IPO Lot Size & Investment Details
Application limits for Retail and HNI investors| Application Category | Lots | Shares | Amount (at Cut-off) |
|---|---|---|---|
| Retail (Min) | 2 Lots | 800 Shares | ₹2,74,400 |
| Retail (Max) | 2 Lots | 800 Shares | ₹2,74,400 |
| S-HNI (Min) | 3 Lots | 1,200 Shares | ₹4,11,600 |
| S-HNI (Max) | 7 Lots | 2,800 Shares | ₹9,60,400 |
| B-HNI (Min) | 8 Lots | 3,200 Shares | ₹10,97,600 |
Q-Line Biotech IPO Live GMP & Movement History
Daily unofficial grey market trends
Current Grey Market Premium
₹109 +31.8%
Estimated Listing Price
₹452.00
| Date | IPO GMP (₹) | Estimated Listing Price | Estimated Listing Gain (%) |
|---|---|---|---|
| 26 May 2026 | ₹101 | ₹444.00 | +29.45% |
| 25 May 2026 | ₹125 | ₹468.00 | +36.44% |
| 20 May 2026 | ₹110.5 | ₹453.50 | +32.22% |
Disclaimer: Grey Market Premium (GMP) figures are purely unofficial and indicative rates traded in the unregulated grey market. GMP is highly volatile and does not guarantee the actual listing price. Always consult a SEBI registered investment advisor before bidding.
Q-Line Biotech IPO Subscription Status
Demand breakdown by investor category
Retail
47.12x
QIB
25.34x
NII / HNI
—
Total
50.82x
About Q-Line Biotech
Q-Line Biotech IPO Reservation & Share Quotas
| Investor Category | Share Offered | Shares (%) |
|---|---|---|
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | 29,69,200 Shares | 50% |
| NII Shares Offered | 8,91,600 Shares | 15% |
| Retail Shares Offered | 20,79,200 Shares | 35% |
Q-Line Biotech IPO Anchor Investors
| Particulars | Details |
|---|---|
| Anchor Bidding Date | 2026 |
| Anchor Investors List | |
| Shares Offered | [.] Shares |
| Anchor Size | [.] Cr. |
| Lock-in Period End Date 50% Shares (30 Days) | 2026 |
| Lock-in Period End Date 50% Shares (90 Days) | 2026 |
Q-Line Biotech IPO Important Dates
| Particular | Dates |
|---|---|
| IPO Open Date | 21 May 2026 |
| IPO Close Date | 25 May 2026 |
| Basis of Allotment | 26 May 2026 |
| Refunds | - |
| Credit to Demat Account | - |
| IPO Listing Date | 29 May 2026 |
Note: The timeline for క్యూ-లైన్ బయోటెక్ IPO is tentative and subject to change.
Q-Line Biotech Promoters and Shareholding Pattern
The promoters of the company are Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal.
| Particular | Shares | % Share |
|---|---|---|
| Promoter Holding Pre Issue | 1,70,74,999 | 96.77% |
| Promoter Holding Post Issue | 2,33,28,199 | -% |
Q-Line Biotech Objects of the Issue & Utilisation of Proceeds
To Be Updated Soon
About Q-Line Biotech IPO
Since its incorporation in 2013, Q-Line Biotech has been involved in the healthcare and diagnostic industry. The firm is known for manufacturing and supplying In-Vitro Diagnostic (IVD) products, medical diagnostic equipment, reagents, rapid test kits, and pathology instruments. The firm has been known to offer high-quality products and services at an affordable price range.
Q-Line Biotech has over 15 years of experience in the diagnostic industry and has served 150+ national and international clients. Moreover, the company also has 12 years of experience in developing and manufacturing various products. Its product range includes haematology, POC testing, clinical chemistry, molecular diagnostics, rapid tests, ELISA, and special diagnostics.
Q-Line Biotech Company Financial Report
To Be Updated Soon
Q-Line Biotech Company Valuation & Key Performance Indicators
To Be Updated Soon
Q-Line Biotech Peer Group Comparison
To Be Updated Soon
Q-Line Biotech Lead Managers & Merchant Bankers
- Hem Securities Ltd.
- Share India Capital Services Pvt. Ltd.
Q-Line Biotech IPO FAQs
Q-Line Biotech IPO opens for subscription on 20 May 2026 and closes on 24 May 2026.
The price band for Q-Line Biotech IPO is set at ₹326.00 to ₹343.00 per share.
The minimum market lot size is 400 shares. A retail investor can apply for a minimum of 1 lot requiring an investment of 800 Shares (₹2,74,400).
The latest Grey Market Premium (GMP) for Q-Line Biotech IPO is ₹109.00. GMP represents the unofficial premium at which shares trade prior to listing.
The basis of allotment for Q-Line Biotech IPO is tentatively scheduled for 25 May 2026, and shares are expected to list on the stock exchanges on 28 May 2026.
The registrar details will be confirmed in the official prospectus.
Q-Line Biotech IPO Analysis & Articles
